Clinical Trials Logo
  1. Home
  2. NHL
  3. NCT04440436

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

NHL Clinical Trial

Official title:
Phase I/II Clinical Study to Evaluate the Safety and Efficacy of IM19 Chimeric Antigen Receptor T Cells(CAR-T) in the Treatment of Recurrent or Refractory (R/R) CD19 Positive Aggressive Non-Hodgkin's Lymphoma

Clinical Trial Summary

This is a phase I/II, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult with R/R Non-Hodgkins Lymphoma in China.

Clinical Trial Description

This is a phase Ⅰ/Ⅱ. The phase I is a single-center study. The main objective is to evaluate the safety of IM19 CAR-T cell therapy for patients with relapsed or refractory CD19-positive invasion of non-Hodgkin's lymphoma. The phase Ⅱ is a multi-center study,The main goal is to evaluate the efficacy of IM19 CAR-T cells in the treatment of patients with relapsed or refractory CD19-positive invasion of non-Hodgkin's lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04440436
Study type Interventional
Source Beijing Immunochina Medical Science & Technology Co., Ltd.
Contact Fei Wu, MD
Phone +8615801390058
Email wufei@immunochina.com
Status Recruiting
Phase Phase 1/Phase 2
Start date June 4, 2020
Completion date June 4, 2035
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04555811 - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Phase 1
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Recruiting NCT03535753 - Safety and Efficacy Evaluation of Decitabine With R-GDP Phase 1
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Completed NCT00513175 - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia N/A
Recruiting NCT05641428 - Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL Phase 2
Recruiting NCT05879744 - A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Phase 1
Completed NCT00342121 - Influence of Corn Farming on the Immune System
Withdrawn NCT01101581 - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Phase 1/Phase 2
Active, not recruiting NCT04139252 - A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients
Terminated NCT04840784 - First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML Phase 1
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1
Terminated NCT02702492 - PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) Phase 1
Completed NCT03527147 - Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) Phase 1
Withdrawn NCT05365100 - A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL Phase 1/Phase 2
Terminated NCT00814983 - Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Phase 1/Phase 2
Withdrawn NCT02847949 - A Study of IGN002 for Refractory NHL Phase 1
Completed NCT00891592 - Umbilical Cord Blood Transplant for Hematological Malignancies Phase 1
Completed NCT00546793 - Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Phase 1/Phase 2
Recruiting NCT03739502 - A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant Phase 2